ClinicalTrials.gg
Status unknownNCT04614740Updated Dec 13, 2022

The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors

A Phase 1/2 interventional study of VC004 in Locally Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Status unknown at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-13.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
174th of 401
115 · median 90
Started
2020
with 25 others
Phase 1/2
48 of 485
23 open now
Registered
163rd of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 174th largest by planned enrollment of the 401 interventional ones that give a count, is one of 26 that started in 2020, is one of 48 in phase 1/2, and was the 163rd registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

Dose-escalation study will be conducted in patients with locally advanced/metastatic solid tumors who have failed standard treatment, or cannot tolerate standard treatment, or have no recommended standard treatment, or do not apply standard treatment, to evaluate the safety, PK, tolerability and effectiveness of VC004. According to the efficacy, safety and PK of dose-escalation study , the investigator and the sponsor jointly determine the dose for dose extension, and evaluate the anti-tumor effect of VC004 on NTRK fusion-positive subjects, and provide more information for RP2D.

According to the tolerability and pharmacokinetic results of dose-escalation study , an appropriate dose or MTD will be selected, namely RP2D, to further assess anti-tumor efficacy and safety in patients with NTRK fusion-positive locally advanced/metastatic solid tumors . ORR will be chosen as the main efficacy indicator to evaluate the anti-tumor efficacy and safety of VC004 .

03

Conditions studied

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

Keywords

  • Safety, Tolerability, Pharmacokinetic, Effectiveness
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures;
  • Male or female, age ≥18 years old
  • Patients with locally advanced or solid tumors diagnosed by histology or cytology, or currently have no standard treatment, have failed the standard treatment, or are intolerant to the standard treatment or are not suitable for the standard treatment at this stage。 The first part of the dose escalation stage: locally advanced or metastatic solid tumors, including but not limited to salivary gland cancer, thyroid cancer, soft tissue sarcoma, liposarcoma, etc.
  • Subject's baseline lesion requirements: According to the definition of v1.1 or RANO, the subject must have at least one (applicable to NTRK fusion-positive locally advanced or metastatic solid tumors)。
  • Subjects with primary central nervous system (CNS) tumors must meet the following criteria (only the first part of the dose expansion phase and the second part are applicable)

    • According to the guidelines or CNS tumor type, have received treatment including radiotherapy and/or chemotherapy, and the interval between radiotherapy and the first treatment with study drug is at least 12 weeks.
    • According to the definition of RANO, there is at least one measurable lesion in magnetic resonance imaging (MRI), which can be visualized on ≥2 axial films with a thickness of 5 mm, and the longitudinal diameters perpendicular to each other are> 10 mm.
    • The imaging examination was performed within 28 days before enrollment. If you receive treatment, a stable dose of glucocorticoid is required at least 5 days before imaging evaluation.
  • The (ECOG) score is ≤2 points (0-1 points are required for the dose-escalation stage)
  • The estimated survival time is ≥12 weeks.
  • The subject must have appropriate organ and hematological functions (have not received blood transfusion, EPO, G-CSF or other medical supportive treatment within 14 days before the administration of the study drug)。
  • Premenopausal women who are likely to have children must have a pregnancy test within 7 days before starting treatment. The pregnancy test must be negative and must be non-lactating; Infertile women may not undergo pregnancy tests and , but they must meet the following requirements: age 50 years or older, not using hormone therapy and menopause for at least 12 months, or have undergone sterilization. All enrolled patients (whether male or female) should take adequate contraceptive measures throughout the treatment period and 180 days after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients have previously received any of the following treatments:

    • Patients have used any cytotoxic chemotherapeutic agents, targeted therapies, immunotherapies, or other anti-cancer drugs in the previous regimen within 4 weeks before the first administration ( e.g.Nitrosourea or mitomycin C for 6 weeks prior to first use of study drug, Oral fluorouracil and small-molecule targeted drugs are administered 2 weeks prior to the first use of the study drug or within 5 half-lives of the drug, whichever is longer.).
    • The time from receiving other experimental drugs or analogues to the first dose does not exceed the drug's 5 half-life or 14 days (whichever is longer).
    • Patients have used chinese herbal medicines and chinese herbal preparations with antitumor as an indication, chinese herbal medicines and chinese herbal preparations with tumor adjuvant therapeutic effect within 14 days before the first administration.
  • Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, procedures)
  • Adverse reactions caused by previous treatment have not recovered to ≤1 grade (the dose-escalation stage does not include ≤2 grade hair loss, and the dose expansion stage and phase II clinical trials are comprehensively evaluated by the investigator).
  • Primary central nervous system (only the first part of the dose escalation phase).
  • Patients are known to have symptomatic or untreated or other central nervous system .CNS lesions that remain stable or show improvement after treatment with complete resection and/or radiation therapy are excluded, but require no to control neurological symptoms within 14 days prior to entry into this study.
  • There is any clinical basis suggesting a severe or uncontrolled systemic disease for which the investigator believes the patient is unsuitable for trial participation or which would affect the patient's compliance with the study protocol, such as stable or decompensated respiratory disease, cerebrovascular disease, liver disease, renal disease, uncontrolled diabetes, aortic dissection, aortic aneurysm, active bleeding-prone body, or those requiring systemic anti-infective therapy.
  • Any clinically serious gastrointestinal abnormality that may affect the ingestion, transit, or absorption of study drugs.
  • Patients have cardiovascular diseases, including:

    • (LVEF) ≤ 50% by echocardiography during the screening period
    • Heart Failure, (NYHA) grade III and above
    • Poorly controlled hypertension (BP ≥ 150/100 mmHg despite use of optimal therapy)
    • Past or current cardiomyopathy
    • Patients with atrial fibrillation and severe arrhythmia with ventricular rate> 100 bpm
    • Unstable ischemic heart disease (myocardial infarction (MI) within 6 months prior to starting study treatment, or angina that requires >1 nitrate per week to control symptoms)
  • interval ≥450ms for males and ≥470ms for females (Fredericka formula: QTcF = QT/RR0.33)
  • Patients had been treated with a strong inhibitor or inducer within 7 days prior to the first administration of the study drug.
  • Currently existing (hepatitis B surface antigen [HbsAg] positive or core antibody [HbcAb] positive and HBV DNA positive), (HCV anti-positive and HCV RNA positive), (HIV) infection and syphilis infection.
  • Patients whom the investigators determine are not suitable for participation in the study for other reasons.
  • Subjects are unwilling or unable to follow the protocol process.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    VC004

    1. Dose escalation stage: subjects in the 50 mg, 100 mg, 200 mg, and 300 mg dose groups took a single oral dose on the first day; starting from the fourth day, each group of subjects took the corresponding dose twice a day. 2. Dose expansion stage: subjects in the 100mg and 200mg dose groups took the corresponding dose twice a day on an empty stomach; 3. Phase II clinical trial stage: oral administration twice a day before meals, and the dosage is to be determined.

    Drug: VC004

Interventions

  • DrugVC004

    25 mg capsules,50 mg capsules,100 mg capsules.

06

What researchers measure

Primary outcomes

  1. Safety&Tolerability

    Adverse events (CTCAE5.0)and/or laboratory testsand/or electrocardiogramand/or echocardiogramand/or vital signsand/or physical examination

    Time frame: 4 years

  2. Phase II recommended dose(RP2D)

    According to the tolerability and pharmacokinetic results of different dose groups completed during the dose escalation phase, an appropriate dose or MTD is selected as RP2D

    Time frame: 1.5 years

  3. Maximum tolerated dose(MTD)(If any)

    If ≥2 cases of DLT are observed at a certain dose (up to 6 subjects), the dose will be considered an intolerable dose, and the previous dose group will be regarded as MTD

    Time frame: 1.5 years

  4. Objective response rate(ORR)

    The proportion of subjects whose best overall response is CR or PR in the study assessed by IRC/investigator according to RECIST v1.1 or RANO

    Time frame: 4 years

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h

  2. Peak time(Tmax)

    Time frame: 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h

  3. half-time(t1/2)

    Time frame: 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h

  4. Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC)

    Time frame: 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h

  5. Apparent volume of distribution(Vz/F)

    Time frame: 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h

  6. Duration of Remission (DOR)

    Time from the first recording of remission (CR or PR) to the first recording of disease progression or death (whichever occurs first)

    Time frame: 2.5 years

  7. Progression-free survival (PFS)

    The time from the subject receiving the first study treatment to the appearance of disease progression or death from any cause (whichever occurs first)

    Time frame: 2.5 years

  8. Overall survival (OS)

    The time from the date of first medication to the date of death from any cause

    Time frame: 2.5years

07

Study locations

9 of 21 sites recruiting
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui 230001, China
    Not yet recruiting
    • Jingmo Yang · Contact
    • Hu Li · Principal investigator
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400030, China
    Not yet recruiting
    • Yuanyuan Yin · Contact
    • Yongsheng Li · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350001, China
    Not yet recruiting
    • Ping Huang · Contact
    • Yu Chen · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530021, China
    Not yet recruiting
    • Yu Lei · Contact
    • Hongxue Wang · Principal investigator
    • Xie Weimin · Principal investigator
  • Hainan Cancer Hospital
    Haikou, Hainan 570312, China
    Not yet recruiting
    • Lin Na · Contact
    • Zhixia Wei · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, He Nan, China
    Recruiting
    • Yuefang Cheng · Contact
    • Suxia Luo · Principal investigator
    • Jiaqiang Wang · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
    • Zhuo Sun · Contact
    • Da Jiang · Principal investigator
  • Harbin Medical Univercity Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Not yet recruiting
    • Xiang Li · Contact
    • Qingyuan Zhang · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hu Nan, China
    Recruiting
    • Yun Jiang · Contact
    • Gang Huang · Principal investigator
  • Jiangsu Province Hospital of Chinese Medicine
    Nanjing, Jiang Su, China
    Recruiting
    • Jungang Yin · Contact
    • Jun Qian · Principal investigator
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Not yet recruiting
    • Huijuan Li · Contact
    • Dongyuan Zhu · Principal investigator
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai 200072, China
    Not yet recruiting
    • Fei Teng · Contact
    • Qing Xu · Principal investigator
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
    Not yet recruiting
    • Guozhong Wang · Contact
    • Shuqing Wei · Principal investigator
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650106, China
    Not yet recruiting
    • Sanhua Na · Contact
    • Yanbin Xiao · Principal investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Not yet recruiting
    • Feiyan Li · Contact
    • Meiyu Fang · Principal investigator
  • Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, China
    Recruiting
    • Ning Li · Contact
    • Yuankai Shi · Principal investigator
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, China
    Recruiting
    • Shixiang Zheng · Contact
    • Ting Wei · Principal investigator
  • Liaoning Cancer Hospital & Institute
    Shenyang, China
    Recruiting
    • Lixuan Wei · Contact
    • Zhendong Li · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, China
    Recruiting
    • Jinhuai Xue · Contact
    • Guowen Wang · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, China
    Recruiting
    • Li · Contact
    • Youhua Zhu · Principal investigator
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, China
    Recruiting
    • Bugela · Contact
    • Huarong Zhao · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Jan 2024, 38 months after the start.

Of 127 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 38 months is below that.

Counting every sponsor, half of 213 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2020
First posted
Nov 4, 2020
StartActual
Nov 20, 2020
Primary completionEst.
Jan 31, 2024
CompletionEst.
Jun 30, 2024
Last update
Dec 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04614740
Responsible party
Sponsor
First posted
Nov 4, 2020
Start date
Nov 20, 2020
Primary completion
Jan 31, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Dec 13, 2022

Study contacts

xiaojuan lai
Contact
lai_xiaojuan@vcarepharmatech.com
15358160458
yuankai shi
principal investigator · Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eratrectinib

Start the discussion